The U.S. companion animal health market size is estimated to reach at USD 13.97 billion in 2030 and is projected to grow at a CAGR of 9.87% from 2025 to 2030. The rising number of pet owners seeking better healthcare services, healthier quality foods, and high-end grooming and training services for their companion animals is a major driver for this market. According to theNational Pet Owners Survey, 90.5 million families in the U.S. own a pet, out of which 69.0 million own a dog. Moreover, high-income families amounted to approximately 60% of the total spending. In recent years, pet adoption has shown immense growth. This is primarily attributed to the fact that people are healthier and happier in the presence of pets, as found by the Human-Animal Bond Research Initiative Foundation (HABRI).
With the rising adoption of companion animals and growing concerns over their health, there comes a direct association with pet insurance. Presently, pet insurance accounts for a small segment in the insurance industry. The Covid-19 pandemic positively impacted the market growth in the U.S. Key players such as Boehringer Ingelheim Animal Health, Chewy, Elanco, MWI Animal Health, Covetrus, and PetIQ focused on expanding their telemedicine solutions into the market as governments relaxed governance to enable more flexible veterinary examinations during the coronavirus pandemic.
Approval of novel therapeutics and companion animal vaccines continues to present this market with lucrative growth opportunities. Ongoing trends for the adoption of e-commerce, pet insurance, veterinary telemedicine, point of care diagnostic testing, and digitalization of veterinary practices are further accelerated by the crisis of COVID-19.
Groundbreaking technological advances are rapidly transforming the pet health industry. These expansions are maximizing the potential for growth. Companies are taking strategic initiatives in pet health, such as the adoption of big data, wearable technologies to monitor pet health, and the inclusion of stem cell therapy. Moreover, established players are focusing on expanding their portfolios. For instance, Elanco acquired Bayer AG’s animal health business unit in August 2019.
The U.S. captured a substantial share of the market. The share attained by this country is primarily a consequence of the presence of prominent market players undertaking extensive expansion strategies. Moreover, the increasing number of R&D investments initiated by the companies is one of the key potential growth factors presumed to be responsible for the sizeable share garnered by the U.S.
Request a free sample copy or view the report summary: U.S. Companion Animal Health Market Report
Based on animal type, the dogs segment led the market with the largest revenue share of 40.57% in 2024 due to the increasing spending on pet care, specifically in developed regions.
By product, the pharmaceuticals segment is expected to gain popularity in the coming years owing to the growing demand to increase pet longevity and rising R&D activities.
On the basis of distribution channel, the e-commerce segment is anticipated to witness rapid growth over the forecast period due to the increased convenience offered to pet owners.
Based on end use, the hospitals & clinics segment led the market with the largest revenue share of 50.68% in 2024. Veterinary hospitals and clinics encourage pet owners to seek out effective treatments by educating them on the value of diagnostics and medication for their pet's health.
Vetiquinol S.A., Zoetis, Merck, Ceva Santé Animale, Boehringer Ingelheim GmbH, and Elanco are some of the major market participants due to their product offerings and strong regional presence.
Companies are adopting various strategies to gain competitive advantages, such as new product development, partnerships, mergers and acquisitions, collaborations, and regional expansion.
Grand View Research has segmented the U.S. companion animal health market report based on animal type, product, distribution channel, end use:
U.S. Companion Animal Health Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
Dogs
Cats
Equine
Others
U.S. Companion Animal Health Product Outlook (Revenue, USD Million, 2018 - 2030)
Biologics
Vaccines
Modified/ Attenuated Live
Inactivated (Killed)
Other Vaccines
Other Biologics
Pharmaceuticals
Parasiticides
Anti-infectives
Anti-inflammatory
Analgesics
Others
Supplements
Diagnostics
Others
U.S. Companion Animal Health Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Retail
E-commerce
Hospital/ Clinic Pharmacies
U.S. Companion Animal Health End Use Outlook (Revenue, USD Billion, 2018 - 2030)
Hospitals & Clinics
Point-of-Care
Others
List of Key Players in U.S. Companion Animal Health Market
Merck & Co., Inc.
Elanco
Boehringer Ingelheim GmbH
Ceva Santé Animale
Zoetis
Virbac
IDEXX Laboratories, Inc.
Mars Inc.
Dechra Pharmaceuticals Plc (EQT)
Vetoquinol S.A.
"The quality of research they have done for us has been excellent..."